Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DisCoVisc, DuoVisc, BioVisc, Healon5, Amvisc Plus · 1 trial · 1 indication
Percentage of corneal endothelial cells lost 2 months after surgery as compared to the number of corneal endothelial cells measured before the operation. Corneal Endothelial Cells are measured by counting the number of cells on an image taken by specular microscope.
| Arm | Type | Description |
|---|---|---|
| DisCoVisc | ACTIVE_COMPARATOR | Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) |
| DuoVisc | ACTIVE_COMPARATOR | Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) |
| BioVisc | ACTIVE_COMPARATOR | Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) |
| Healon5 | ACTIVE_COMPARATOR | AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) |
| Amvisc Plus | ACTIVE_COMPARATOR | Bausch \& Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) |
| Name | Type | Description |
|---|---|---|
| DisCoVisc | DEVICE | DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure. |
| DuoVisc | DEVICE | DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure. |
| BioVisc | DEVICE | BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure. |
| Healon5 | DEVICE | Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure. |
| Amvisc Plus | DEVICE | Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure. |
Inclusion Criteria: * Unilateral operable cataracts Exclusion Criteria: * Preoperative Endothelial Cell Count (ECC) ≤1500 cells/mm2 * Intraocular Pressure (IOP) \> 21 * History of ocular inflammation * Systemic or ocular diseases affecting corneal endothelium
DisCoVisc is an ophthalmic viscosurgical device used during cataract surgery. It is designed to help maintain space and protect ocular tissues during the procedure. The drug is being developed by Alcon Inc. for the treatment of cataracts.
DisCoVisc is developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. The company is conducting clinical development of the product for use in cataract surgery.
DisCoVisc is in Phase 3 clinical development. It is an investigational product and has not yet been approved by regulatory authorities. The Phase 3 trial for DisCoVisc has been completed.
DisCoVisc has one completed Phase 3 clinical trial registered under NCT00732225, titled "DisCoVisc Comparative Evaluation." The trial enrolled 173 participants with cataracts in the United States and was actively controlled, meaning it compared DisCoVisc against another treatment.
DisCoVisc, DuoVisc, BioVisc, Healon5, and Amvisc Plus are all ophthalmic viscosurgical devices used in cataract surgery. They are distinct products, though they may be used for similar purposes during the procedure.